This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Sana Biotechnology has a new $50 million tool in its toolbox. That’s according to a study in Nature Communications led by CRISPR pioneer Feng Zhang at the Broad Institute of MIT and Harvard, which has licensed its technology to Beam. Sana CEO and president Steve Harr. Sana Photo).
A biotech prize for turning chemicals into food On the biotechnology front, the Mars Society plans to offer an incentive prize for methods that use microbes to convert simple chemicals, such as methane or methanol, into food. “Ask it anything you want, and you get the answer in multiple personalities,” he said.
LinkedIn Photos) Seattle startup Cyrus Biotechnology is spinning out a business that will expand access to the company’s software technology, with the potential of supporting innovation in drug development, agriculture, synthetic biology and manufacturing.
Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. Pacific Northwest biotechs that have gone public this year include Sana Biotechnology, which raised $587 million in its February IPO and Impel NeuroPharma, which raised $80 million through its IPO in April.
Under the agreement, Takeda has options to exclusively license programs at the preclinical stage and will take products to the clinic and through commercialization. Ainsworth, a veteran biotech exec, has led the company since 2018 when he replaced Matthew Scholz , who founded the company in 2009 and is now CEO of Oisín Biotechnologies.
based biotechnology company struck a deal with Merck in which the pharmaceutical powerhouse will provide a $600 million upfront payment and make a $1 billion equity investment to continue development of treatments for breast cancer. Seattle Genetics CEO Clay Siegall. Seattle Genetics Photo). Merck will own about 2.9
Washington State University assistant professor and Appiture Biotechnologies co-founder Georgina Lynch. WSU Photo). The biotech and healthtech community in Eastern Washington has a loyal base of startups that laud their local connections and the support of a tight-knit group of entrepreneurs.
The publicly traded Seattle biotech company hired investment bank SVB Securities to review potential alternatives including a sale, merger, asset divestiture or licensing. “It Last week Novo Nordisk announced it was laying off 86 workers and shutting a lab site in Seattle.
Nvidia hopes to allay those concerns by striking a licensing deal with stock image library Getty Images, which says it will pay royalties to artists on revenue generated by models trained on the works in its database. It named biotechnology company Amgen as one of the first users of the service.
The UW has licensed the exclusive rights of this intellectual property to the startup. Researchers in Daggett’s lab used computer modeling to discover the role played by alpha-sheets, a structure formed by proteins, in creating the deposits, and this research is the underpinning of AltPrep’s technology.
Founded in 2018, Vouched helps companies verify the identity of customers and users by examining driver’s licenses and other forms of identification. Sana Photo) — Dhaval Patel joined Sana Biotechnology as executive vice president and chief scientific officer. It can provide fraud detection of a person in real-time.
Kawas co-founded Athira (originally M3 Biotechnology) in 2011. Papers with altered images were cited in an earlier patent licensed by the company from WSU. Laursen , a pharmaceutical and biotechnology executive; Sylvia S. The company investigators concluded that Kawas had “ altered ” — not enhanced — the data-containing images.
Juno veterans went on to start or fill leadership positions at Sana Biotechnology, Lyell Immunopharma, Umoja Biopharma, Shape Therapeutics, GentiBio, Eliem Therapeutics, Genemod, Century Therapeutics, Silverback Therapeutics, Tune Therapeutics, Affini-T Therapeutics, and others. Sana Biotechnology. Photo courtesy of William Canestaro).
Leek: There’s everything from licensing technologies to identifying ways to support trainees who see themselves growing into a more startup-like community rather than going into academics. And then pouring the institutional support behind it can really explode cool ideas out into the public.
Founded in 2010, Leafly’s online marketplace lets customers shop and select cannabis products from licensed retailers. Leafly is among a group of Seattle-area companies going public via the SPAC route, joining a list that includes Rover, Nautilus Biotechnology, and Getty Images. Shares were up about 7% as of Monday afternoon.
RELATED: Pfizer will acquire Seattle-area biotech giant Seagen for $43 billion Pfizer markets two approved ADCs and last year out-licensed two ADC candidates to biotech company Pyxis. “We didn’t do as good a job as Seagen” with ADCs said Bourla in the call.
So you buy a processing unit design from somebody like Arm in the UK, who is very popular, and then maybe you need the USB interface, so you get a USB IP block, which you license. So you decide, “I want to build a controller chip.” Moderna, for example, had been working on it for a decade with $1 billion of private capital invested.
And I’ll earn my A-class license on iRacing…. Our region is very well positioned to capitalize on the huge inflows of investment capital into biotechnology and other tech sectors over the past year which are projected to continue for at least another year if not longer. Magdalena Balazinska , professor and director of the Paul G.
We organize all of the trending information in your field so you don't have to. Join 83,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content